Toxicological aspects of the use of tamoxifen in patients with breast cancer
DOI:
https://doi.org/10.5281/zenodo.8388090Keywords:
Cancer. Breast cancer. Tamoxifen. Toxic effectsAbstract
Breast cancer is a serious global public health problem. TMX is a drug used as one of the therapeutic lines against this neoplasm, but it can cause toxic effects due to its antiestrogenic action. The formation of toxic TMX metabolites can significantly affect treatment adherence and clinical therapeutic management of patients. The general objective of this research article is to carry out an integrative literature review of the toxicological aspects of the use of tamoxifen in patients with breast cancer. 15 articles were found in the online databases, which met the research inclusion and exclusion criteria. It is concluded that TMX is a drug used as one of the therapeutic lines against this neoplasm, but the formation of toxic metabolites of TMX can significantly affect adherence to treatment and clinical therapeutic management of patients. Therefore, the presence of the pharmacist, especially the pharmacist in oncology, is of great importance to resolve problems related to pharmacotherapy, aiming to successfully achieve the desired therapeutic objectives, preventing the appearance of toxic effects that compromise pharmacological therapy and health. of the patient.
Downloads
References
BOTELHO, L.L.R.; CUNHA, C. C. A.; MACEDO, M. O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade, v. 5, n. 11, p. 121-136, 2011.
DALFRÉ, N.; JUNIOR, A. B. USO DE TAMOXIFENO E DESENVOLVIMENTO DE CÂNCER ENDOMETRIAL: REVISÃO DE LITERATURA. International Journal of Health Management Review, v. 6, n. 2, 2020.
DAVIES, C.; PAN, H.; GODWIN, J.; GRAY, R.; ARRIAGADA, R.; RAINA, V.; ABRAHAM, M.; MEDEIROS, A.V.H.; BADRAN, A.; BONFILL, X.; BRADBURY, J.; CLARKE, M.; COLLINS, R.; DAVIS, S.R.; DELMESTRI, A.; FORBES, J.F.; HADDAD, P.; HOU, M.F.; INBAR, M.; KHALED, H.; KIELANOWSKA, J.; KWAN, W.H.; MATHEW, B.S.; MITTRA, I.; MÜLLER, B.; NICOLUCCI, A.; PERALTA, A.; PERNAS, F.; PETRUZELKA, L.; PIENKOWSKI, T.; RADNIKA, R.; RAJAN, B.; RUBACH, M.T.; TORT, S.; URRÚTIA, G.; VALENTINI, M.; WANG, Y.; PETO, R. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 9;381(9869):805-16. 2013.
DEVITA, V.; LAWRENCE, T. J.; ROSENBERG, S.A. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 11th ed. Philadelphia: Wolters Kluwer; 2019.
COELHO, A.; SANTOS, M.; CAETANO, R.; PIOVESAN, C.; FIUZA, L.; MACHADO, R.; FURINI, A. Predisposição hereditária ao câncer de mama e sua relação com os genes BRCA1 e BRCA2: revisão da literatura. Revista Brasileira de Análises Clínicas (RBAC). São Paulo, 2017. Disponível em: http://www.rbac.org.br/artigos/predisposicao-hereditaria-ao-cancer-de-mama-e-sua-relacao-com-os-genes-brca1-e-brca2-revisao-da-literatura/. Acesso em: 01 Mar.2023.
CORDEIRO, M. N.; PINTO, E. M.; BRETANI, H. Hereditary breast cancer: diagnosis and management. Revista da Associação Médica Brasileira, 64(3), 234–242. 2018.
GOLSHAN, M.; LOIBL, S. Early-stage breast cancer: is less ever more? The Lancet Oncology. [s.l.], v. 18, n. 3, p. 286-287, 2017.
HALE, M. J.; HOWELL, A.; DOWSETT, M.; CUZICK, J.; SESTAK, I. Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. Breast. 54:216-221, 2020. Disponível em: <https://pubmed.ncbi.nlm.nih.gov/33160147>. Acesso em: 10 de Mar. 2023.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA. Estimativa 2022: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2022. Base de dados. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2022-incidencia-de-cancer-no-brasil.pdf. Acesso em: 10 Mar. 2023.
LIEN, E. A. The role of tamoxifen in breast cancer endocrine therapy: a narrative review. Pharmaceuticals, v. 13, n. 11, p. 401, 2020.
LOPES, A.L.; COSTA, L.D.; DE PAULA, C.A.A.; GARCIA, J.M.; REIS, R.M. Genetic and epigenetic alterations in breast cancer: Implications for personalized medicine. Frontiers in Genetics, 11. 2020.
MAHAJAN, P. M.; DANDEKAR, S. P. Tamoxifen-induced ocular toxicity: a review. Expert Opinion on Drug Safety, v. 19, n. 4, p. 409-416, 2020
MONTEIRO, R.; AZEVEDO, I. Chronic exposure to tamoxifen induces DNA damage and oxidative stress in human liver HepG2 cells. Toxicology in Vitro, v. 58, p. 69-75, 2019.
PALACIOS, J.; ROBLES-FERNANDEZ, I.; BARRAGAN, E. Genes involved in hereditary breast and ovarian cancer: beyond BRCA1 and BRCA2. International Journal of Cancer, 149(7), 1487–1499. 2021.
PEREIRA, B., CHIN, S.F.; RUEDA, O. The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nat Commun 7, 11479. 2016.
REBBECK, T. R., FRIEBEL, T.M.; FRIEDMAN, E.; HAMANN, U.; HUO, D.; KWONG, A.; COUCH, F.J. Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. Human Mutation, 39(5), 593–620. 2018.
RUSSO, J.; RUSSO, I. H. The role of estrogen in breast cancer. In: ESTROGEN ACTION, SELECTIVE ESTROGEN RECEPTOR MODULATORS AND WOMEN'S HEALTH: PROGRESS AND PROMISE. Springer, Cham. p. 207-222. 2019.
SALAZAR, R. F. S.; DE FÁTIMA, C.C.; HORN, R. C.; RANGEL, C.O.; BANDEIRA, V.A.C.; GELATTI, G.T. Avaliação da adesão ao tratamento com Tamoxifeno por mulheres com câncer de mama. Revista de Epidemiologia e Controle de Infecção, v. 10, n. 1, p. 86-93, 2020.
SILVA, T. M. Hormonioterapia como alternativa no tratamento do câncer de mama. Trabalho de Conclusão de Curso (graduação) - Centro Universitário do Planalto Central Apparecido dos Santos, Faculdade de Farmácia, 2021.
VASCONCELOS, P. H. M.; DA SILVA, N.; PIMENTEL, A.S.P.; MELO, W.C.; ALEMIDA, A.C.G. Eficácia e as vantagens do uso de tamoxifeno na terapia hormonal adjuvante do carcinoma de mama in situ: revisão sistemática. Brazilian Journal of Development, v. 7, n. 11, p. 108830-108841, 2021.
